Last reviewed · How we verify
STSG
CUTISS AG's STSG is an autologous dermo-epidermal skin substitute in Phase 2 and Phase 3 trials for burns and reconstructive surgery. The drug leverages advanced tissue engineering to promote skin regeneration and reduce scarring, positioning it as a potential best-in-class therapy.
At a glance
| Generic name | STSG |
|---|---|
| Also known as | Split-thickness skin graft |
| Sponsor | CUTISS AG |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- STSG CI brief — competitive landscape report
- STSG updates RSS · CI watch RSS
- CUTISS AG portfolio CI